- Home
- OESX vs GRCE Comparison
OESX vs GRCE Comparison
Compare OESX & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OESX
- GRCE
- Stock Information
- Founded
- OESX 1996
- GRCE 2002
- Country
- OESX United States
- GRCE United States
- Employees
- OESX N/A
- GRCE N/A
- Industry
- OESX Building Products
- GRCE
- Sector
- OESX Consumer Discretionary
- GRCE
- Exchange
- OESX Nasdaq
- GRCE NYSE
- Market Cap
- OESX 27.5M
- GRCE 30.9M
- IPO Year
- OESX 2007
- GRCE N/A
- Fundamental
- Price
- OESX $0.83
- GRCE $3.33
- Analyst Decision
- OESX Strong Buy
- GRCE
- Analyst Count
- OESX 1
- GRCE 0
- Target Price
- OESX $3.00
- GRCE N/A
- AVG Volume (30 Days)
- OESX 66.2K
- GRCE 29.8K
- Earning Date
- OESX 11-06-2024
- GRCE 11-13-2024
- Dividend Yield
- OESX N/A
- GRCE N/A
- EPS Growth
- OESX N/A
- GRCE N/A
- EPS
- OESX N/A
- GRCE N/A
- Revenue
- OESX $91,649,000.00
- GRCE N/A
- Revenue This Year
- OESX $13.74
- GRCE N/A
- Revenue Next Year
- OESX $14.83
- GRCE N/A
- P/E Ratio
- OESX N/A
- GRCE N/A
- Revenue Growth
- OESX 14.40
- GRCE N/A
- 52 Week Low
- OESX $0.81
- GRCE $1.98
- 52 Week High
- OESX $1.53
- GRCE $3.60
- Technical
- Relative Strength Index (RSI)
- OESX 36.71
- GRCE N/A
- Support Level
- OESX $0.92
- GRCE N/A
- Resistance Level
- OESX $0.94
- GRCE N/A
- Average True Range (ATR)
- OESX 0.04
- GRCE 0.00
- MACD
- OESX -0.01
- GRCE 0.00
- Stochastic Oscillator
- OESX 5.00
- GRCE 0.00
About OESX Orion Energy Systems Inc.
Orion Energy Systems Inc is a developer, manufacturer, and seller of lighting and energy management systems. The company segments include Orion Lighting Segment, Orion Maintenance Segment and Orion Electric Vehicle Charging Segment. It derives maximum revenue from Lighting Segment.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.